Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dietary supplement allergy claims

This article was originally published in The Tan Sheet

Executive Summary

San Clemente, Calif.-based Metagenics will no longer dispute FDA's contention that the statements "promotes a healthy immune response in people who may be sensitive to environmental substances" and "promotes healthy histamine levels" are disease claims. FDA first flagged four structure/function claims for the allergy supplement Perimine in a March 2003 "courtesy letter." The firm argued allergies do not constitute a disease state because they are not "damage to an organ, part, structure or system of the body such that it does not function properly, or a state of health leading to such dysfunctioning." FDA disagreed, maintaining "an allergic response is, in fact, unambiguously a consequence of damage to a system (the immune system) such that it does not function properly in that it is hypersensitive to allergens." The agency adds that the claims cannot be modified so that they are not disease claims...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel